GSK Investigational Site
Verona, Veneto, 37134, Italy
NCT Number: NCT00861484
The purpose of this study is to determine if the administration of GSK958108 can delay ejaculation in patients with primary premature ejaculation as measured by the ejaculatory latency time (ELT) using the masturbation model and sexual visual stimulation, and to evaluate the safety and tolerability of GSK958108 in healthy men with PE
Looking for future studies?
Notify Me18 year–50 year
Male
Interventional
Phase 1
Verona, Veneto, 37134, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Coated Tablets 1 mg
Coated tablets
Time frame: 50 minutes
Time frame: 8 weeks
Time frame: From predose to 30 hours post-dose
GlaxoSmithKline
Industry
A Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of a Single Oral Dose of GSK958108 on Ejaculatory Latency Time (ELT) in Male Patient Suffering From Premature Ejaculation
Acronym: PoM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07300774
Ejaculatory Dysfunction, Genital Diseases
Istanbul, Beşiktaş, Turkey (Türkiye)
View Trial DetailsNCT04207723
Ejaculatory Dysfunction, Genital Diseases
Bogotá, Colombia
View Trial DetailsNCT07036497
Ejaculatory Dysfunction, Genital Diseases
Bursa, Nilufer, Turkey (Türkiye)
View Trial DetailsNCT02109302
Ejaculatory Dysfunction, Genital Diseases
La Chaussée-Saint-Victor, France
View Trial Details